Neuronetics Stock News

MALVERN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve t

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of 0% and 0.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Clearance allows for more access to non-drug, noninvasive treatment for patients suffering from MDD or OCD Clearance allows for more access to non-drug, noninvasive treatment for patients suffering fr

MALVERN, Pa., May 06, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve t

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 20% and 10.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) delivered earnings and revenue surprises of 26.92% and 11.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of 0% and 6.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

The ISM services PMI rose to 58.3 in March from 56.5 in the previous month. Investors, meanwhile, focused on some notable insider trades.

MALVERN, Pa., March 08, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to five new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to each employee''s entry into employment with the Company.

STIM earnings call for the period ending December 31, 2021.

Neuronetics Inc (NASDAQ: STIM ) reported Q4 FY21 sales of $15.02 million , down 4% Y/Y, exceeding previously issued guidance of $13.0 million - $14.0 million and the consensus of $14.43 million. U.S. revenue decreased by 3% during the quarter, and international revenue decreased by 13% Y/Y due to lower NeuroStar Advanced Therapy System sales and treatment session … Full story available on Benzinga.com

Neuronetics Inc (NASDAQ: STIM) reported Q4 FY21 sales of $15.02 million, down 4% Y/Y, exceeding previously issued guidance of $13.0 million - $14.0 million and the consensus of $14.43 million. U.S.

Neuronetics, Inc. (STIM) CEO Keith Sullivan on Q4 2021 Earnings Call Transcript